NCT00225251

Wellbutrin XL for Dysthymic Disorder

Double-Blind Treatment of Outpatients With Dysthymic Disorder With Wellbutrin XL

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: St. Luke's-Roosevelt Hospital Center · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a ten-week, double-blind study of Wellbutrin XL in outpatients with dysthymic disorder, a form of low-grade chronic depression. We hypothesize that patients taking Wellbutrin XL will show greater improvement in depression symptoms and psychosocial functioning than patients taking placebo.

Detailed description

This is a ten-week, double-blind, placebo-controlled study designed to evaluate the tolerability, dosing and efficacy of Wellbutrin XL in outpatients who meet Diagnostic and Statistical Manual-IV criteria for early onset, primary type dysthymic disorder (low-grade chronic depression). It is hypothesized that patients taking Wellbutrin XL will show greater improvement in depression symptoms and psychosocial functioning than patients taking placebo.

Conditions

• Dysthymic Disorder

Interventions

Type	Name	Description
DRUG	bupropion XL	Antidepressant medication
OTHER	Placebo	Placebo

Timeline

• Start date: 2004-11-01
• Primary completion: 2008-05-01
• Completion: 2008-06-01
• First posted: 2005-09-23
• Last updated: 2015-11-26
• Results posted: 2014-11-24

Locations

1 site across 1 country: United States